GlassScriptPhysician profile
Jeffrey Robert Gruhler
NPI 1639445752
$1,716.41
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $159 · 2022: $1,085 · 2023: $21.13 · 2024: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $299.22 | 2019-2024 | Spravato |
| Abbvie INC. | $227.90 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $151.86 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $115.82 | 2022-2024 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $115.03 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $102.00 | 2021-2022 | |
| Tris Pharma INC | $98.71 | 2022-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $84.57 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.88 | 2022 | |
| Vanda Pharmaceuticals INC. | $77.49 | 2021-2024 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $64.62 | 2022 | |
| Corium, LLC | $59.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $50.05 | 2021-2024 | Rexulti |
| Noven Therapeutics, LLC | $48.68 | 2022 | |
| Almatica Pharma LLC | $38.84 | 2024 | Loreev Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $27.18 | 2024 | |
| Adlon Therapeutics L.P. | $19.75 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.11 | 2022 | |
| Lundbeck LLC | $14.81 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $13.89 | 2021 | |
| Organon LLC | $10.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gruhler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.